Core Viewpoint - The company, Hunan Warrant Pharmaceutical Co., Ltd., is focusing on raising funds for technological innovation, with a total fundraising amount not exceeding 250 million yuan, aimed at supplementing working capital and enhancing its competitive edge in the pharmaceutical industry [2][7]. Group 1: Company's Main Business - The company specializes in the research, production, and sales of chemical drug formulations, chemical raw materials, and traditional Chinese medicine formulations, positioning itself as a high-tech enterprise with multiple R&D centers [1][6]. - It has established a high-end pharmaceutical industrialization platform with an "integrated raw material and formulation" advantage and is continuously developing a specialized innovative traditional Chinese medicine industrialization platform [3][4]. Group 2: Fundraising Plan - The total amount raised from the issuance will be used entirely to supplement working capital after deducting issuance costs, with 60 million yuan already deducted from the fundraising scale due to prior financial investments [2][5]. - The company aims to enhance its profitability and comprehensive competitiveness by integrating various resources and focusing on its core business [2][4]. Group 3: R&D and Innovation - The company has significantly increased its R&D investment, with R&D expenses as a percentage of revenue rising from 6.86% in 2022 to 11.21% in 2024 [4]. - It has developed a comprehensive R&D system and established several core technology platforms, enabling it to maintain a strong competitive edge in the pharmaceutical market [6][8]. Group 4: Market Position and Future Prospects - The company has obtained 76 formulation registration certificates and has a growing market share in key therapeutic areas such as digestion, respiration, and anti-infection [3][4]. - The fundraising will support the company's ongoing R&D efforts in innovative drugs and high-end generic drugs, enhancing its product offerings and overall competitiveness [7][8].